A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2015
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BECAUSE
- Sponsors Bayer HealthCare Pharmaceuticals
- 09 Mar 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 18 Dec 2008 Additional trial identifier (91449, EudraCT2005-001540-23) added as reported by ClinicalTrials.gov.
- 07 Dec 2006 Status change